China Biotech Weekly #1: The ~$12B Signal — Why GSK-Hengrui Rewrites the Playbook

The Week in Brief

This week in China Biotech Weekly. The China-to-West deal flow continues to accelerate — in the first half of 2025, Chinese companies were counterparty to 38% of all Big Pharma licensing deals above $50M. That is not a trend. That is a structural shift in where the global industry sources its pipeline.

This week, we lead with GSK's blockbuster multi-asset agreement with Hengrui Medicine (恒瑞医药), unpack the BIOSECURE Act's compliance calendar, and lay out what the recent mega-deal cluster means for BD strategy in 2026 and beyond.

Deal Table: The China Mega-Deal Cluster (2025–2026)

The concentration of billion-dollar-plus deals over the past twelve months has no precedent. Five transactions alone account for over $47 billion in total deal value.

Three patterns emerge:

1. Upfront discipline varies wildly. AstraZeneca paid just $100M upfront on an $18.5B headline — a 0.5% upfront-to-total ratio. Pfizer paid $1.25B on $4.8B — a 26% ratio. The spread reflects asset maturity, competitive dynamics, and negotiating leverage. BD teams benchmarking upfronts need to look at the full structure, not the headline.

1. Bispecifics dominate. Three of the five deals involve bispecific antibodies or multi-specific formats. Chinese biotechs — particularly those spun out of antibody engineering platforms — have built genuine first-or-best-in-class positions in this space. The BNT-327 deal (PD-L1 x VEGF bispecific) was the inflection point; subsequent deals have confirmed the thesis.

1. Small molecules are back. The AstraZeneca-CSPC (石药集团) deal — a novel lipoprotein disruptor — is a reminder that China's innovation is not limited to biologics. CSPC's medicinal chemistry capabilities produced a differentiated cardiovascular asset that commanded the largest headline value in the dataset. Do not sleep on Chinese small molecule platforms.

---

CDE Filing Watch

A few notable developments from China's Center for Drug Evaluation (国家药品监督管理局药品审评中心) over the past two weeks:

• Hengrui (恒瑞医药) submitted a new IND for an undisclosed bispecific in a solid tumor indication — consistent with the pipeline breadth signaled by the GSK deal. This asset appears to be retained for domestic rights.
• BeiGene (百济神州) filed a supplemental NDA for zanubrutinib in a new combination regimen, continuing its strategy of expanding the label of its global anchor asset.
• Innovent Biologics (信达生物) received CDE acceptance for a Phase III trial of its next-generation PD-1/VEGF bispecific, entering an increasingly crowded but commercially massive field.

The CDE continues to process filings at an accelerated pace following its 2024 review reforms. Average IND review timelines have compressed to approximately 40 business days for priority-designated assets, making the Chinese regulatory pathway increasingly competitive with FDA timelines for early-stage filings.

We will track material CDE filings weekly, with a focus on assets that have ex-China licensing potential or that signal competitive dynamics relevant to Western BD pipelines.

---

BIOSECURE Compliance Update

Current status: The BIOSECURE Act was signed into law on December 18, 2025, as part of the National Defense Authorization Act (NDAA Section 851). The law directs the Office of Management and Budget (OMB) to publish a list of Biotechnology Companies of Concern (BCCs) by December 2026. Federal agencies will then have a defined transition period before contracting prohibitions take full effect. Key timeline:

• December 18, 2025: BIOSECURE Act signed into law (NDAA Sec. 851)
• By December 2026: OMB must publish the BCC list — this is the trigger event
• 2027–2028: FAR (Federal Acquisition Regulation) amendments expected
• Post-FAR publication: Federal procurement restrictions take effect

Who is likely on the list? The legislation specifically names entities already on the Section 1260H list as probable BCCs:

• BGI Genomics (华大基因)
• MGI Tech (华大智造)
• Complete Genomics (BGI subsidiary)

WuXi AppTec (药明康德) and WuXi Biologics (药明生物) remain under sustained congressional pressure and were central to the legislative debate, but they have not been formally designated as BCCs at this time. Their status will depend on the OMB review process. Both companies have undertaken corporate restructuring and data-security measures intended to address congressional concerns, though the political dynamics remain unpredictable. What this means in practice: If your supply chain touches BGI (华大基因), MGI, or Complete Genomics — whether for sequencing services, instrumentation, or data analysis — begin mapping alternatives now. For WuXi-dependent CDMO workflows, the risk is real but the timeline allows for contingency planning. Do not wait for the BCC list to start. One nuance often missed: BIOSECURE restricts federal contracting, not private commercial activity. A pharma company using WuXi (药明康德) for commercial manufacturing is not directly prohibited — but the reputational and political risk is material, and secondary restrictions (e.g., federal grant recipients) could expand the blast radius. Structure your risk assessment accordingly.

---

Corporate Ownership Map: WuXi AppTec (药明康德)

This week's entity deep-dive: the company at the center of the BIOSECURE debate.

Ge Li (李革), the Columbia-trained chemist who founded WuXi in 2000, controls approximately 25% of voting rights through a multi-layered holding structure spanning Cayman, BVI, and mainland China entities. The corporate chain: Ge Li → WuXi AppTec (2359.HK / 603259.SS) → 52% ownership of WuXi Biologics (2269.HK) → 50.1% of WuXi XDC (2268.HK). Source: HKEX Disclosure of Interests filings.

WuXi AppTec has at least 16 operating subsidiaries across mainland China, the US, and Europe — from STA Pharmaceutical (合全药业, the small molecule CDMO arm) to WuXi Advanced Therapies (Philadelphia, cell and gene therapy) to Crelux GmbH (Munich, structural biology).

The question compliance teams are asking: If WuXi AppTec is designated as a BCC under Category B, does Category C automatically capture WuXi Biologics and WuXi XDC? The statute says yes for "subsidiaries." The corporate structure was designed to create legal separation — but the ownership chain is traceable.

Key number: 34 US-listed companies have explicitly named WuXi in BIOSECURE-related SEC risk disclosures, across 292 individual filings. That is 14.8% of all companies that filed BIOSECURE disclosures. Source: EDGAR full-text search.

---

Benchmarks

Average upfront payments for China-origin deals: $52M (2022) → $141M (2025). That is a 170% increase in three years. China is no longer bargain biotech. The Pfizer-3SBio deal paid $1.25B upfront on $4.8B total — a 26% ratio that would have been unthinkable for a Chinese asset in 2022.

---

Takeaways for BD Teams

1. The multi-asset deal is the new mega-deal. GSK-Hengrui signals that leading Chinese innovators now have portfolio depth sufficient to support framework agreements. If your BD process is built around single-asset evaluation, adapt it. The companies that move to portfolio-level engagement will get first pick.

1. Upfront benchmarks are misleading without structural context. The $100M upfront on an $18.5B deal (AstraZeneca-CSPC) and the $1.25B upfront on a $4.8B deal (Pfizer-3SBio) are both rational — but they reflect entirely different risk profiles, competitive positions, and negotiation dynamics. Build your term sheets from the asset forward, not from comps backward.

1. BIOSECURE is a compliance event, not a China exit signal. The Act targets specific entities involved in genomic data and federal contracts. It does not prohibit — and cannot practically prohibit — licensing innovative therapeutics from Chinese companies. The 38% deal share figure makes the point: Western pharma needs Chinese innovation. Structure your China engagement to separate supply-chain risk (addressable) from pipeline access (essential).

1. Watch bispecifics and multi-specifics closely. Chinese companies have built durable competitive advantages in antibody engineering, particularly in bispecific and bispecific-ADC formats. The next wave of billion-dollar deals will likely come from this space. If you are not actively scouting Chinese bispecific platforms, your competitors are.

1. Map your CDMO exposure now. If any part of your clinical or commercial supply chain touches BGI, WuXi, or their subsidiaries, start the alternatives assessment today. The BCC list deadline is December 2026 — but FAR rulemaking and procurement reviews will create pressure well before that. Companies that have a transition plan ready will avoid the scramble.

---

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan